Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

NCT06735820 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Malignant Peripheral Nerve Sheath Tumor (MPNST)
Neurofibromatosis 1 (NF1)
Atypical Neurofibroma

Interventions

DRUG: APG-115
DRUG: Selumetinib

Sponsor

AeRang Kim

Collaborators

[object Object]